ReviewCureus2023
Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Chronic kidney disease and cardiovascular risk: Pathophysiology and interventional approaches - systematic review.Medicine · 2025Pooled it
- Explainable machine learning integrating bioelectrical impedance for 6-month cardiovascular risk in peritoneal dialysis.Renal failure · 2026Article
- Heat-KilledJournal of microbiology and biotechnology · 2026Article
- Arterial stiffness and incident chronic kidney disease risk: a two-phase retrospective cohort study.BMC nephrology · 2026Article
- Development and evaluation of cardiovascular disease risk prediction models for patients with type 2 diabetes.Scientific reports · 2026Article
- Multimodal Detection of Subclinical Cardiovascular Disease in Chronic Kidney Disease.Cardiorenal medicine · 2026Review
- Prognostic Implications of Chronic Kidney Disease Stage on Outcomes After Percutaneous Coronary Intervention.Journal of cardiovascular development and disease · 2025Article
- Long-Term Outcomes of Nephron-Sparing Versus Radical Nephrectomy in Stage 4 Chronic Kidney Disease.Journal of clinical medicine · 2025Article
- Article
- Novel approaches and applications in identifying DNA methylation markers of cardio-kidney-metabolic disease.Epigenomics · 2025Review
- New and Emerging Biomarkers in Chronic Kidney Disease.Biomedicines · 2025Review
- Parathyroid Hormone Levels as an Independent Predictor of Ischemic Heart Disease in Stage 3-5 Non-Dialysis Chronic Kidney Disease: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- A Plant-Dominant Low-Protein Diet in Chronic Kidney Disease Management: A Narrative Review with Considerations for Cyprus.Nutrients · 2025Review
- Article
- The Hidden Link between Chronic Kidney Disease and Lung Injury.American journal of respiratory cell and molecular biology · 2024Article
- Kidney-Sparing Surgery for Upper Tract Urothelial Carcinoma-Modalities, Outcomes, and Limitations.Journal of clinical medicine · 2024Review
- Analytical Insights into Methods for Measuring Ischemia-Modified Albumin.Molecules (Basel, Switzerland) · 2024Review
- Metabolomic and Physiological Effects of a Cardiorenal Protective Diet Intervention in African American Adults with Chronic Kidney Disease.Metabolites · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Kidney Disease (CKD) has emerged as a global healthcare challenge affecting a significant portion of the world's population. This comprehensive narrative review delves into the intricate relationship between CKD and cardiovascular disease (CVD). CKD is characterized by kidney damage persisting for at least three months, often with or without a decline in glomerular filtration rate (GFR). It is closely linked with CVD, as individuals with CKD face a high risk of cardiovascular events, making cardiovascular-associated mortality a significant concern in advanced CKD stages. The review emphasizes the importance of precise risk assessment using biomarkers, advanced imaging, and tailored medication strategies to mitigate cardiovascular risks in CKD patients. Lifestyle modifications, early intervention, and patient-centered care are crucial in managing both conditions. Challenges in awareness and recognition of CKD and the need for comprehensive interdisciplinary care are highlighted. Recent advances in research offer promising therapies, such as SGLT2 inhibitors, MRAs, GLP-1R agonists, and selective endothelin receptor antagonists. Stem cell-based therapies, gene editing, and regenerative approaches are under investigation. Patient-physician "risk discussions" and tailored risk assessments are essential for improving patient outcomes. In conclusion, the review underscores the complexity of the interconnected CKD and cardiovascular health domains. Ongoing research, innovative therapies, and personalized healthcare will be instrumental in addressing the challenges, reducing the disease burden, and enhancing well-being for individuals facing CKD and cardiovascular issues. Recognizing the intricate connections between these conditions is imperative for healthcare providers, policymakers, and researchers as they seek to improve the quality of care and outcomes for affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.